2023-10-08 05:59:00
Title: Thailand Establishes National Biopharmaceutical Production Pilot Factory for Quality Medicine
Date: [insert date]
In today’s era, humans face increased risks of various diseases. Producing drugs to treat them in a timely manner is essential. Therefore, it is another necessary thing. For this reason, the National Center for Genetic Engineering and Biotechnology (Biotech), the National Science and Technology Development Agency (NSTDA), and King Mongkut’s University of Technology Thonburi (KMUTT) have cooperated to establish a “National Biopharmaceutical Production Pilot Factory” (NBF) to develop the production process of biopharmaceuticals and vaccines. Let Thailand have quality medicine that can be produced by oneself without the need to wait for imports from abroad.
Asst. Prof. Dr. Lalinthip Horcharoen, a researcher at the National Biopharmaceutical Production Facility, KMUTT, said that the NBF was built as a connection unit of researchers with the testing of biological drugs and vaccines at the pre-clinic and clinical phase I, II stages. NBF has a unit that covers the development of small-scale production processes (greater than or equal to 5 liters) pilot level (5 – 30 liters) for the entire upstream process (fermentation/cell culture) and downstream (purification) to production in a pilot plant with a maximum capacity of 2,000 liters. NBF also has equipment and a laboratory for biomaterial and vaccine analysis that is ready to support analysis from the basic characteristics to a level that requires advanced techniques and modern tools, such as sequence analysis of genetic material and proteins, etc.
The National Biopharmaceutical Production Pilot Plant is therefore a laboratory for furthering advanced research from Lab-scale to Pilot-scale, ready to help develop the potential of personnel, knowledge, and advanced production technology, supporting the country’s biopharmaceutical industry.
Dr. Warinthorn Songkasiri, Director of the Biochemical Engineering and Systems Biology Research Group at Biotech NSTDA, said that the establishment of a pilot plant to produce biomaterials and high-value substances in the country recognizes the bottleneck in research connectivity in biopharmaceuticals. These are drugs produced using biotechnology processes that are being tested in humans and commercialized.
“Biotech has continuously researched and developed the production of biological medicines. Whether it is the development of production processes for biological materials and vaccines at the laboratory level, several platforms have been obtained, such as the monoclonal antibody platform, which is a biological material used as an anti-cancer drug, the plasmid DNA platform, and the protein platform for treating diseases such as PCV2d, which is a Thai collaboration vaccine by KMUTT Biotech and UK partners under project cooperation GCRF includes analysis in the BPCL laboratory that provides protein and genetic analysis services. In addition, BIOTEC and private partners are collaborating with NBF to produce pig vaccines for other diseases that are endemic in Thailand, including: PEDV and PRRS. Currently, cell banks for virus cultivation are already being produced at this pilot plant.”
The National Biopharmaceutical Production Pilot Factory is considered an important place for further research to support the biopharmaceutical industry of Thailand.
This collaboration between Biotech, NSTDA, and KMUTT will contribute to Thailand’s ability to produce quality medicine independently and enhance the country’s biopharmaceutical capabilities. It marks a significant milestone in the nation’s fight against diseases by ensuring timely access to essential medications.]
#Watch #clip #Amazing #National #Biopharmaceutical #Production #Pilot #Factory #Find #answer #biological #drug